icotec ag Receives Approvals for Two KONG® VBR Spinal Systems Made with BlackArmor® and Ti-iT® in Europe and the US

June 18, 2020

icotec ag announces that the KONG®-TL and the KONG®-C vertebral body replacement systems with the unique Titanium coating (Ti-iT®) receive FDA 510(k) clearance in the United States and CE approval in Europe.

icotec ag CEO Roger Stadler said, “This is exciting news for icotec ag and our team as it allows us to expand our portfolio in multiple countries simultaneously, to include implants made from radiolucent, nonmetallic BlackArmor® material with a 360° osseoconductive Ti-iT® pure titanium coating.”

The surgical replacement of vertebral bodies is a common procedure after the removal of tumors from the spinal column or after a serious spinal fracture. A vertebral body replacement implant (VBR) is used to reconstruct and stabilize the spinal column. The surgical requirements for these stabilization procedures are met by the broad, innovative and technology platform developed by icotec ag.

  • The fully modular design of these VBR systems with endplates in various profiles, sizes, angles and alignments complements the expandability afforded by the KONG®-TL VBR E (thoracolumbar) for the thoracic and lumbar spine providing surgeons with a great deal of flexibility in the surgical planning process. With the KONG®-C VBR for the cervical spine, the curved implant body ensures optimal adaptation to the anatomy of the patient.
  • The 360° Ti-iT® pure titanium coating from icotec ag allows for the rapid engraftment of bone onto the implant thanks to the optimized osseoconductive structure.
  • The unique icotec BlackArmor® Carbon/PEEK implant material enables artefact-free imaging to be carried out and, most notably, the improved planning, application, and follow-up care of radiotherapy for patients with tumors.

With over 15 years of clinical success and more than 40,000 implants made from the unique BlackArmor® material, icotec ag is the leading provider of Carbon/PEEK implants. As the global market leader in the surgical treatment of vertebral tumors, icotec ag has set a target of establishing a complete product portfolio that provides patients with improved therapy options. “With the imminent market launch of the KONG®-TL/C vertebral body replacement systems in Europe and the US, we have made significant strides toward achieving this target,” commented Roger. He continues, “These systems perfectly complement the icotec ag pedicle screw systems already in surgical use.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version